STAT+: House bill aimed at Chinese biotechs is advancing
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: cancer
STAT+: Ono Pharmaceutical to acquire Deciphera Pharma, maker of cancer drugs, for $2.4 billion
Ono Pharmaceutical of Japan said Monday it will acquire Deciphera Pharmaceuticals, a Boston-based maker of…
STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition
MorphoSys is dealing with an emerging safety issue related to pelabresib, the experimental treatment for…
Opinion: STAT readers respond to First Opinion essays on site-neutral payments, free medical school tuition, and more
“Former HHS secretaries: Congress should adopt site-neutral payments for health care,” by Alex Azar and…
Are You at Risk for CKM Syndrome?
The American Heart Association (AHA) has defined a new syndrome— and strategies for addressing it—in…
Vitamin Supplements: Yes, or No?
A 2023 survey found that 74 percent of U.S. adults take some kind of dietary…
Recognize Symptoms of Gynecologic Cancers
As we age, the risk of certain health issues, including gynecologic cancers, increases. Arming ourselves…
STAT+: A spending frenzy on obesity drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: Balancing hope and reality: The promise and peril of blood-based colorectal cancer screening
As a gastroenterologist and cancer researcher, my mission is to help my patients live longer,…
STAT+: Day One drug for common childhood brain tumor approved by FDA
Day One Biopharmaceuticals said Tuesday the Food and Drug Administration approved its pill for one…
Opinion: Bashing accelerated approval isn’t supported by the data
The Food and Drug Administration’s accelerated approval program aims to speed “approval of drugs that…
STAT+: Dana-Farber retracts string of studies in systematic review of data integrity
An ongoing investigation into data integrity at Dana-Farber Cancer Institute has resulted in a string…
STAT+: Cancer vaccine startup launches with $54 million, Spark veteran as CEO
A new startup focused on creating vaccines for cancers, influenza, and potentially even HIV launched…
STAT+: Mass General Brigham is ready to move on without Dana-Farber, CEO says
CHICAGO — The split between Dana-Farber Cancer Institute and Mass General Brigham has been messy….
Gas prices are hurting biotech
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: When a cancer drug fails, oncologists often fly blind. A precision technique might light the way
It seemed as if Logan Jenner had the best possible chance for a cure. Diagnosed…
AskBio CSO steps down, has new project in stealth mode
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: Cancer vaccines gain momentum, after years of disappointing results
SAN DIEGO — Cancer vaccines have traveled a potholed road over the last decade. But…
NCI director expresses optimism about next era of cancer research, despite shrinking budget and brain drain
SAN DIEGO — Kimryn Rathmell, director of the National Cancer Institute, gestured toward the screen…
Opinion: Cancer is a killer. So is the fear of it
The widespread attention to the recent revelations of cancer diagnoses by Princess Catherine, actress Olivia…
STAT+: Biden administration urged to license prostate cancer drug patents in a bid to lower its cost
In the latest gambit to lower the cost of a pricey medicine, three advocacy groups…
STAT+: MassMutual is rolling out free genetic testing for members, a dicey area for life insurers
One of the country’s biggest life insurers is venturing into genetic testing, an area that’s…
STAT+: New liquid biopsy screening test for pancreatic cancer shows promise in early data
For the vast majority of pancreatic cancer cases, the tumor grows undetected until it has…
STAT+: WHO scientists question Grail’s plan for evaluating its multi-cancer Galleri blood test
A new analysis published Sunday challenges the clinical trial endpoint the cancer screening firm Grail…
STAT+: About half of cancer drugs given accelerated approval don’t improve survival or quality of life
SAN DIEGO — For decades, the Food and Drug Administration’s accelerated approval pathway has helped…
STAT+: Cancer is rising among the young. Study suggests it’s because their cells are aging faster
SAN DIEGO — Cancer cases among younger people have been rising for years, a trend…
Opinion: STAT readers on biotech and national security, liquid-only diets before colonoscopy, and the value of weight loss drugs
STAT now publishes selected Letters to the Editor received in response to First Opinion essays…
New data on liquid biopsy for colorectal cancer detection still underwhelms
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Genmab to buy ProfoundBio for $1.8 billion, the latest deal focused on targeted chemotherapies
LONDON — The Danish firm Genmab said Wednesday it would acquire ProfoundBio for $1.8 billion…
.jpg)
STAT+: Gritstone Bio says personalized cancer vaccine falls short in key trial
Gritstone Bio said Monday afternoon that its personalized cancer vaccine didn’t induce more responses than…
Why a bill meant to stop surprise medical bills hasn’t worked
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money…
Aardvark Therapeutics gearing up for $200 million IPO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Scientists uncover potential path to treating deadly childhood tumor
Most targeted cancer drugs work like tranquilizer darts, snaring an overzealous gene that has spurred…
What’s Congress going to do with WuXi?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Does decaf coffee contain a harmful additive? Advocates want to ban a certain chemical in the brew
WASHINGTON — There’s a fight brewing over the future of decaf coffee. Consumer health advocates…
Brazil’s plan for low-cost CAR-Ts
New biotech newsletter launching tomorrow. Don’t miss out. Good morning, everyone. Damian here with the…
Opinion: What the public might learn from Kate Middleton, the latest ‘famous patient’
There was a time when the last thing a celebrity would do would be to…
Frontline: Brain nerve cell repair; cancer stem cells; T-cell therapy
Brain Nerve Cell Repair Offers Hope for Alzheimer’s Disease Nerve cells in the brain require…
The U.S. banned asbestos, but its health impact will still be felt for decades
A new rule announced by the Environmental Protection Agency this week puts an end to…
Novo is building a really big computer
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO
Robert Ross had thought he would take more time off after his previous company, Surface…
Opinion: The evidence is clear: A liquid-only diet before a colonoscopy is unnecessary
Since colorectal cancer is on the rise in people younger than age 50, national guidelines…
STAT+: As targeted radiation field heats up, AstraZeneca to pick up Fusion Pharmaceuticals in $2 billion deal
LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more…
STAT+: I was wrong about Geron’s blood cancer drug. Now, is it a takeover target?
I was wrong about Geron. For years, I’ve believed — and declared publicly — that…
STAT+: FDA advisers back CAR-T therapies in blood cancer, despite safety concerns
A panel of expert advisers to the Food and Drug Administration on Friday voted in…
Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And…
STAT+: EPA restricts cancer-causing chemical used to sterilize medical devices
On Thursday, the Environmental Protection Agency finalized limits on a carcinogenic gas called ethylene oxide…
Is CAR-T safe for early-stage patients?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Small studies offer hope CAR-T can fight an aggressive brain cancer
A series of new studies are raising hopes that CAR-T, a process in which treatments…
STAT+: In large trial, Guardant Health’s blood test detects colon cancer, but less reliably at earliest or precancerous stages
Doctors have been eagerly waiting for data on Guardant Health’s new blood-based colorectal cancer screening…